

Special Issue

Antibiotics and the Human Gut Microbiome: Dysbioses and Accumulation of Resistances

Message from the Guest Editor

Antibiotics are life-saving treatments that have been in use for decades to protect against bacterial pathogens raised in both humans and animals. Homeostasis of the gut microbiota is currently recognized as a major contributor to human health. Dysbiosis (reduced diversity) of gut microbiota is associated with increased antibiotics and antibiotic drug doses. The purpose of this Special Issue is to address (1) the effects of antibiotic use on gut microbiota composition and function, (2) the effects of antibiotic-induced microbiota changes in immunity, metabolism, and health, and (3) the role of the gut microbiota as antibiotics, as well as the role of drug resistance reservoirs. Both original papers and review articles are welcome, and will be considered for publication in this Special Issue of *Antibiotics*.

Guest Editor

Dr. Pedro Barata

Centro Hospitalar Universitário do Porto, Universidade Fernando Pessoa, Porto, Portugal

Deadline for manuscript submissions

closed (15 November 2022)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.2
Indexed in PubMed



mdpi.com/si/117122

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.2
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)